MBRX

MBRX

USD

Moleculin Biotech Inc. Common Stock

$0.497+0.014 (2.836%)

Real-time Price

Healthcare
Biotechnology
United States

Price Chart

Loading Chart...

Key Metrics

Market Metrics
Company Fundamentals
Trading Stats

Market Metrics

Open

$0.483

High

$0.502

Low

$0.470

Volume

2.28M

Company Fundamentals

Market Cap

24.6M

Industry

Biotechnology

Country

United States

Trading Stats

Avg Volume

4.00M

Exchange

NCM

Currency

USD

52-Week Range

Low $0.25Current $0.497High $3.65

Related News

GlobeNewswire

Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia "MIRACLE" Clinical Trial at the 14th Annual Acute Leukemia Meeting

HOUSTON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat

View more
Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia "MIRACLE" Clinical Trial at the 14th Annual Acute Leukemia Meeting
GlobeNewswire

Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin

HOUSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat

View more
Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin
GlobeNewswire

Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer

Atlantic Health, a leading provider of health care based in New Jersey, to conduct the investigator-initiated Phase 1B/2 study Preclinical studies indicate Annamycin targets key factors in pancreatic cancer HOUSTON,

View more
Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer
PR Newswire

Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions

Equity InsiderNews Commentary – Conventional small molecule approaches have struggled to address genetic defects and complex disease mechanisms,...

View more
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions